FY2027 Earnings Forecast for Agenus Issued By William Blair

Agenus Inc. (NASDAQ:AGEN - Free Report) - Investment analysts at William Blair lifted their FY2027 earnings estimates for shares of Agenus in a research note issued to investors on Wednesday, June 4th. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($2.21) per share for the year, up from their prior forecast of ($2.51). The consensus estimate for Agenus' current full-year earnings is ($12.55) per share.

Agenus (NASDAQ:AGEN - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.58. The company had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million.

A number of other analysts have also commented on the stock. HC Wainwright raised shares of Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price objective on the stock in a research report on Wednesday. Wall Street Zen upgraded shares of Agenus from a "strong sell" rating to a "hold" rating in a research note on Thursday, May 22nd. B. Riley restated a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Finally, Robert W. Baird lifted their target price on Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Agenus currently has an average rating of "Hold" and an average price target of $14.00.

Agenus Stock Performance

NASDAQ:AGEN opened at $5.16 on Friday. The stock has a 50-day simple moving average of $2.89 and a 200 day simple moving average of $2.94. Agenus has a 52-week low of $1.38 and a 52-week high of $18.74. The company has a market cap of $141.47 million, a PE ratio of -0.46 and a beta of 1.48.

Institutional Investors Weigh In On Agenus

A number of large investors have recently added to or reduced their stakes in AGEN. Apollon Wealth Management LLC bought a new stake in Agenus in the 4th quarter valued at $55,000. Virtu Financial LLC bought a new stake in Agenus in the 4th quarter valued at about $51,000. Bank of Montreal Can acquired a new position in shares of Agenus during the 4th quarter worth approximately $69,000. Barclays PLC increased its holdings in shares of Agenus by 17.7% during the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock worth $90,000 after purchasing an additional 4,924 shares during the period. Finally, Gilead Sciences Inc. acquired a new stake in shares of Agenus in the fourth quarter valued at approximately $635,000. Institutional investors own 61.46% of the company's stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.